Article
Endocrinology & Metabolism
Kohei Kaku, Takashi Kadowaki, Yutaka Seino, Taro Okamoto, Masayoshi Shirakawa, Asako Sato, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman
Summary: Adding ipragliflozin 50 mg once daily to sitagliptin 50 mg once daily monotherapy significantly improved glycemic control and was generally well tolerated in Japanese patients with type 2 diabetes.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Xu Liu, Yang Liu, Hongzhong Liu, Haiyan Li, Jianhong Yang, Pei Hu, Xinhua Xiao, Dongyang Liu
Summary: Imigliptin and alogliptin, after 13 days of treatment, were shown to decrease glycemic levels by improving beta-cell function. Comparing OMM with HOMA or SUIT results, glucose stimulation may be more sensitive for detecting changes in beta-cell function.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Masayoshi Shirakawa, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman
Summary: In Japanese patients with type 2 diabetes, adding sitagliptin to ipragliflozin monotherapy provided significant improvement in glycemic control and was generally well tolerated.
DIABETES OBESITY & METABOLISM
(2021)
Article
Pharmacology & Pharmacy
Eiji Kutoh, Alexandra N. Kuto, Midori Akiyama, Eri Ozawa, Rumi Kurihara
Summary: The aim of this study was to investigate the regulation of adipose tissue insulin resistance with DPP-4 inhibitors in treatment-naive subjects with T2DM and examine its relation to other diabetic parameters. The results showed that compared to other DPP-4 inhibitors, alogliptin was able to reduce adipose tissue insulin resistance and certain lipid parameters. This study provides initial evidence of a DPP-4 inhibitor's potential to regulate adipose tissue insulin resistance and suggests that adipo-IR is associated with non-LDL-C lipid parameters.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yutaka Umayahara, Tsunehiko Yamamoto, Hiroki Yokoyama, Nobuichi Kuribayashi, Hideaki Jinnouchi, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
Summary: This study investigated whether early initiation of alogliptin improved long-term cardiovascular outcomes. The results showed that early use of alogliptin was not associated with a reduced risk of composite cardiovascular disease, which could be attributed to fewer events and/or the addition of DPP-4 inhibitors during the follow-up period.
SCIENTIFIC REPORTS
(2023)
Article
Nutrition & Dietetics
Kate M. Bermingham, Mohsen Mazidi, Paul W. Franks, Tyler Maher, Ana M. Valdes, Inbar Linenberg, Jonathan Wolf, George Hadjigeorgiou, Tim D. Spector, Cristina Menni, Jose M. Ordovas, Sarah E. Berry, Wendy L. Hall
Summary: This study characterized the variability and correlations of postprandial metabolite changes in a large cohort. The majority of metabolites showed significant changes after a meal, particularly in very large lipoprotein particles and ketone bodies. Strong correlations were observed between fasting and postprandial metabolites, although some metabolites showed weak correlations.
Review
Pharmacology & Pharmacy
Mohammed Alrouji, Hayder M. Al-kuraishy, Ali K. Al-buhadily, Ali I. Al-Gareeb, Engy Elekhnawy, Gaber El-Saber Batiha
Summary: Parkinson's disease (PD) is caused by the degeneration of dopaminergic neurons in the substantia nigra (SN) and current management options focus on symptom relief. However, there is a need for novel treatments that can effectively manage both motor and non-motor symptoms of PD. Dipeptidyl peptidase 4 (DPP-4) inhibitors have shown promising results in protecting against PD. This study aims to uncover the mechanism of DPP-4 inhibitors in managing PD.
PHARMACOLOGICAL REPORTS
(2023)
Review
Neurosciences
A. Young Sim, Sumit Barua, Jong Youl Kim, Yong-ho Lee, Jong Eun Lee
Summary: Alzheimer's disease (AD) is characterized by memory loss and cognitive decline, and has been linked to type 2 diabetes mellitus (T2DM). The pathophysiological relationship between the two diseases involves factors such as amyloid plaques accumulation and oxidative stress, with potential therapeutic drugs including DPP-4 inhibitors and SGLT2 inhibitors.
FRONTIERS IN NEUROSCIENCE
(2021)
Review
Environmental Sciences
Nasr E. Nasr, Kadry M. Sadek
Summary: Diabetes mellitus is a global disease with various complications. The gut may release a pancreatic stimulant in response to nutritional ingestion. Researchers have been exploring the use of incretins to treat diabetes.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2022)
Article
Endocrinology & Metabolism
Marcel H. A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H. H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens J. Holst, A. H. Jan Danser, Jaap A. Joles, Daniel H. van Raalte
Summary: In adults with type 2 diabetes, the dipeptidyl peptidase-4 inhibitor linagliptin did not reduce postprandial hyperfiltration compared to the sulphonylurea glimepiride. However, it appeared to increase the filtration fraction after a meal by potentially raising blood pressure or efferent arteriolar resistance.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, Deborah Ancelle, Sara Barraud, Lyse Bordier, Aurelie Carlier, Nicolas Chevalier, Christine Coffin-Boutreux, Emmanuel Cosson, Anne Dorange, Olivier Dupuy, Pierre Fontaine, Benedicte Fremy, Florence Galtier, Natacha Germain, Anne-Marie Guedj, Etienne Larger, Stephanie Laugier-Robiolle, Bruno Laviolle, Lisa Ludwig, Arnaud Monier, Nathanaelle Montanier, Philippe Moulin, Isabelle Moura, Gaetan Prevost, Yves Reznik, Nadia Sabbah, Pierre-Jean Saulnier, Pierre Serusclat, Camille Vatier, Matthieu Wargny, Samy Hadjadj, Pierre Gourdy, Bertrand Cariou
Summary: A study on 2449 type 2 diabetes patients with COVID-19 found no significant association between the use of DPP-4 inhibitors and disease severity. Therefore, it is safe to continue using DPP-4 inhibitors for diabetes management during the COVID-19 pandemic.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Thomas Klein, Harald Tammen, Michael Mark, Elisa Benetti, Denis Delic, Cornelia Schepers, Maximilian von Eynatten
Summary: The post hoc analysis of MARLINA-T2D trial data found that urinary DPP-4 protein levels could predict UACR response to linagliptin treatment, with medium levels at baseline showing improved UACR outcomes. Patients with lower or higher levels did not show the same improvement, suggesting varying importance of DPP-4 as a pathophysiological factor in T2D-associated kidney disease. Urinary DPP-4 may serve as a useful biomarker for predicting UACR improvement with linagliptin treatment.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, General & Internal
Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
Summary: This retrospective study found that DPP-4 inhibitors can decrease the risk of renal function decline in patients with type 2 diabetes, especially for younger patients, those with better baseline eGFR, no hyperlipidemia or concurrent use of statins.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Kare I. Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W. Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack, Jil Billy Mamza, Ruiqi Zhang, Toshitaka Yajima, Issei Komuro, Takashi Kadowaki
Summary: In patients with type 2 diabetes without prevalent cardiovascular and renal disease, the use of SGLT2i was associated with a lower risk of heart failure and chronic kidney disease compared to DPP4i. There were no significant differences in the risk of stroke and myocardial infarction between the two groups. This multinational observational study suggests that SGLT2i may have better clinical outcomes in patients with type 2 diabetes who are free from cardiovascular and renal disease.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
James Heyward, Jacob Christopher, Sudipa Sarkar, Jung-Im Shin, Rita R. Kalyani, G. Caleb Alexander
Summary: From 2015 to 2019, there was a slight decrease in ambulatory diabetes visits in the United States, with a decline in metformin monotherapy and an increase in the use of GLP-1 receptor agonists and SGLT2 inhibitors as first-line therapies. Second-line therapy saw decreases in DPP-4 inhibitors and sulphonylureas, while SGLT2 inhibitors and GLP-1 receptor agonists increased in use.
DIABETES OBESITY & METABOLISM
(2021)
Article
Health Care Sciences & Services
Gijs F. N. Berkelmans, Stephanie H. Read, Soffia Gudbjornsdottir, Sarah H. Wild, Stefan Franzen, Yolanda van der Graaf, Bjorn Eliasson, Frank L. J. Visseren, Nina P. Paynter, Jannick A. N. Dorresteijn
Summary: This study compared the validity and robustness of five methods for handling missing data in cardiovascular disease risk prediction models. The results showed that median imputation had similar validity and robustness to more complex methods, as long as the most important predictor variables were not missing.
JOURNAL OF CLINICAL EPIDEMIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Araz Rawshani, Naveed Sattar, Darren K. McGuire, Oskar Wallstrom, Ulf Smith, Jan Boren, Goran Bergstrom, Elmir Omerovic, Annika Rosengren, Bjorn Eliasson, Deepak L. Bhatt, Aidin Rawshani
Summary: The study found that the incidence of valvular disease is increasing among patients with diabetes. In type 2 diabetes, systolic blood pressure, body mass index, and renal function were found to be associated with valvular lesions.
Article
Medicine, Research & Experimental
Marja-Riitta Taskinen, Elias Bjornson, Niina Matikainen, Sanni Soderlund, Joel Ramo, Mari-Mia Ainola, Antti Hakkarainen, Carina Sihlbom, Annika Thorsell, Linda Andersson, Per-Olof Bergh, Marcus Henricsson, Stefano Romeo, Martin Adiels, Samuli Ripatti, Markku Laakso, Chris J. Packard, Jan Boren
Summary: This study investigates the impact of apoC-III on lipoprotein metabolism in individuals with a loss-of-function mutation in the APOC3 gene. The results demonstrate that lowering apoC-III levels significantly affects the metabolism of lipoproteins and remnants, potentially having important implications for cardiovascular disease prevention.
Article
Multidisciplinary Sciences
Araz Rawshani, Darren K. McGuire, Elmir Omerovic, Naveed Sattar, John J. V. McMurray, Ulf Smith, Bjorn Redfors, Lennart Bergfeldt, Bjorn Eliasson, Jan Boren, Deepak L. Bhatt, Goran Bergstrom, Aidin Rawshani
Summary: This study investigated the association between type 2 diabetes and cardiac arrhythmias and conduction disturbances. The results showed that patients with diabetes had a higher risk of arrhythmias and conduction abnormalities, but among patients with all risk factors controlled within target range, the excess risk associated with diabetes was virtually not evident.
SCIENTIFIC REPORTS
(2023)
Article
Cardiac & Cardiovascular Systems
Bjorn Eliasson, Jan Ekelund, Cecilia Nagorny Holmberg, Michael Lyng Wolden, Kasper Sommer Matthiessen, Stefan James
Summary: This study compares the prescribing practices in Sweden with the 2021 ESC guidelines for cardiovascular protection in patients with type 2 diabetes. The analysis highlights the high incidence of major adverse cardiovascular events (MACE) in patients with a very high cardiovascular disease risk and suggests that prescribing cardiovascular-protective glucose-lowering medication, such as semaglutide, could potentially prevent a significant number of MACE.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Multidisciplinary Sciences
Helena A. K. Lapatto, Minna Kuusela, Aino Heikkinen, Maheswary Muniandy, Birgitta W. van der Kolk, Swetha Gopalakrishnan, Noora Pollanen, Martin Sandvik, Mark S. Schmidt, Sini Heinonen, Sina Saari, Juho Kuula, Antti Hakkarainen, Janne Tampio, Tuure Saarinen, Marja-Riitta Taskinen, Nina Lundbom, Per-Henrik Groop, Marja Tiirola, Pekka Katajisto, Marko Lehtonen, Charles Brenner, Jaakko Kaprio, Satu Pekkala, Miina Ollikainen, Kirsi H. Pietilainen, Eija Pirinen
Summary: Nicotinamide riboside (NR), a precursor of nicotinamide adenine dinucleotide (NAD(+)), has shown promise in improving obesity-associated mitochondrial dysfunction and metabolic syndrome. However, short-term clinical trials have not yielded positive results. This study aimed to investigate the long-term effects of NR supplementation on mitochondrial biogenesis and metabolic health in humans. The results showed that NR improved NAD(+) metabolism, muscle mitochondrial number, myoblast differentiation, gut microbiota composition, and epigenetic control of gene expression. However, it did not improve adiposity or metabolic health.
Article
Cardiac & Cardiovascular Systems
Naveed Sattar, John McMurray, Jan Boren, Araz Rawshani, Elmir Omerovic, Niklas Berg, Janita Halminen, Kristoffer Skoglund, Bjorn Eliasson, Hertzel C. Gerstein, Darren K. McGuire, Deepak Bhatt, Aidin Rawshani
Summary: The goal of this study was to analyze the trends in cardiovascular events and cardiometabolic risk factor levels in individuals with type 2 diabetes (T2D) and matched control subjects. The results showed a decreasing trend in the risk and rates of atherosclerotic complications and heart failure in individuals with T2D, although the incidence of heart failure has plateaued in recent years. Modifiable risk factors within target levels were associated with lower risks for outcomes.
Letter
Endocrinology & Metabolism
Carlos A. Celis-Morales, Bjorn Eliasson, Naveed Sattar
Article
Cardiac & Cardiovascular Systems
Frida Lener, Gudrun Hoskuldsdottir, Kerstin Landin-Wilhelmsen, Cecilia Bjorkelund, Bjorn Eliasson, Lars Fandriks, Ville Wallenius, My Engstrom, Karin Mossberg
Summary: This study investigated the relationship between nutritional deficiencies and anaemia in patients who reported use of supplementation two years after bariatric surgery versus patients who do not. The results indicated that iron deficiency or anaemia may not be prevented by substitutional treatment per current guidelines after bariatric surgery and highlights there is reason to ensure adequate preoperative micronutrient levels.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2023)
Review
Cell Biology
Annika Nerstedt, Ulf Smith
Summary: In recent years, there has been a significant increase in the prevalence of obesity, leading to a growing interest in adipose tissue as a metabolically dynamic and endocrine organ. Obesity can lead to the development of metabolic diseases such as type 2 diabetes. Cellular senescence, a mechanism of aging, has been found to play a role in metabolic tissues and age-related conditions, including obesity.
JOURNAL OF CELL COMMUNICATION AND SIGNALING
(2023)
Article
Cell Biology
Havard Attramadal, Sushanta K. Banerjee, Brahim Chaqour, Gary Fisher, Lester Lau, Bernard Perbal, Ulf Smith, Herman Yeger
Summary: To celebrate the 20th anniversary of the CCN society and hold the first post-Covid-19 live meeting, the ICCNS executive board chose Nice as the venue for the 11th International workshop on the CCN family of genes. Colleagues from other cell signaling fields were invited to present their work overview and future directions of their laboratory. Additionally, the JCCS Editorial Board members were invited to a special session for open discussions on all aspects of the journal.
JOURNAL OF CELL COMMUNICATION AND SIGNALING
(2023)
Article
Endocrinology & Metabolism
Marja-Riitta Taskinen, Niina Matikainen, Elias Bjornson, Sanni Soderlund, Jussi Inkeri, Antti Hakkarainen, Helka Parviainen, Carina Sihlbom, Annika Thorsell, Linda Andersson, Martin Adiels, Chris J. Packard, Jan Boren
Summary: This study investigated the hypothesis that individuals with type 2 diabetes on statin therapy may have significant abnormalities in the metabolism of intestinally derived lipoproteins. The findings suggest that in these individuals, there are increased production and longer circulation time of ApoB-48-containing lipoproteins, which may contribute to residual cardiovascular disease risk.
Article
Cardiac & Cardiovascular Systems
Elias Bjornson, Martin Adiels, Marja-Riitta Taskinen, Stephen Burgess, Aidin Rawshani, Jan Boren, Chris J. Packard
Summary: In this study, the association between triglyceride-rich lipoproteins (TRL) and coronary heart disease (CHD) was investigated using population data from the UK Biobank. The results suggest that TRL/remnant cholesterol has a stronger and independent association with CHD compared to LDL cholesterol. Moreover, different genetic clusters impact TRL/remnants and LDL differentially, with TRL/remnants exhibiting a higher atherogenicity per particle than LDL.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Nikolaus Marx, Massimo Federici, Katharina Schuett, Dirk Mueller-Wieland, Ramzi A. Ajjan, Manuel J. Antunes, Ruxandra M. Christodorescu, Carolyn Crawford, Emanuele Di Angelantonio, Bjorn Eliasson, Christine Espinola-Klein, Laurent Fauchier, Martin Halle, William G. Herrington, Alexandra Kautzky-Willer, Ekaterini Lambrinou, Maciej Lesiak, Maddalena Lettino, Darren K. Mcguire, Wilfried Mullens, Bianca Rocca, Naveed Sattar
EUROPEAN HEART JOURNAL
(2023)
Review
Medicine, Research & Experimental
Rosa Spinelli, Ritesh Kumar Baboota, Silvia Gogg, Francesco Beguinot, Matthias Bluher, Annika Nerstedt, Ulf Smith
Summary: Cell senescence (CS) plays a crucial role in the connection between aging and chronic disorders, and CS is more prevalent in major metabolic tissues with aging. However, CS is also increased in adult obesity, type 2 diabetes (T2D), and nonalcoholic fatty liver disease, regardless of aging. Dysfunction and inflammation are common features of senescent tissues, affecting both progenitor cells and mature differentiated cells. Recent studies have found that hyperinsulinemia and insulin resistance (IR) can promote CS in human adipose and liver cells. Conversely, increased CS also promotes cellular IR, indicating their interdependence. Additionally, increased adipose CS in T2D is not solely determined by age, BMI, or hyperinsulinemia, suggesting premature aging. These findings suggest that senomorphic/senolytic therapy could be important for treating common metabolic disorders.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
